Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
|Articles|March 1, 1998
Supplements and Featured Publications
- Clinical and Economic Aspects of Obesity Management: A Managed Care Perspective
- Volume 4
- Issue 3 Suppl
Participating Faculty
Advertisement
Articles in this issue
over 28 years ago
Obesity: Why Is It Worth Another Look?over 28 years ago
Obesity Management: A Comprehensive Planover 28 years ago
Clinical Efficacy and Safety of Antiobesity Agentsover 28 years ago
Weight Management Partnership: MCOs and Employersover 28 years ago
Selected Abstractsover 28 years ago
CME/CPE Quizover 28 years ago
BibliographyAdvertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.
Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
3
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
4
5 Things to Know About HHS's Interim Peptide Compounding Policy
5